Small molecule tyrosine kinase inhibitors (such as gefitinib and erlotinib) and monoclonal antibodies (such as cetuximab), each with their distinct mechanisms of action, have been developed for use in targeting EGFR in a number of cancers [43, 44]. Here, EGFR is linked to cancer.